Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511
Joseph Kim, MD
Medical Oncology, Hematology & Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Director, Prostate Cancer Research
Education & Training
- FellowNational Institutes of Health (2013)
- ResidentEmory University School of Medicine (2010)
- MDWake Forest University School of Medicine (2007)
Languages Spoken
- English
- 한국어 (Korean)
Additional Information
Honors & Recognitions
- Cancer Clinical Investigator Team Leadership Award (CCITLA): NCI (2021)
- Young Investigator Award: Conquer Cancer Foundation, American Society of Clinical Oncology (2013)
- Merit Award: Conqer Cancer Foundation, American Society of Clinical Oncology (2013)
Professional Service
- ASCO-SEP (2021 - Present): Editor
- Frontiers Oncology (2019 - Present): Reviewer
- Current Oncology Reports (2015 - Present): Editor
- American Association for Cancer Research (2014 - Present): Member
- Society of Immunotherapy of Cancer (2013 - Present): Member
- American Society of Clinical Oncology (2010 - Present): Member
Publications
- Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022 PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.
- Kim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.
- Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord JP, Gordon M, Kim JW, Sarkar I, Yuen K, Kadel EE, Mariathasan S, O'Hear C, Narayanan S, Fassò M, Carroll S, Powles T. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 3360-3369. PMID: 33568344, DOI: 10.1158/1078-0432.CCR-20-1981.
- Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU International 2021, 127: 435-444. PMID: 32969563, PMCID: PMC8265825, DOI: 10.1111/bju.15227.
- Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology 2020, 9: 1847846. PMID: 33312760, PMCID: PMC7714520, DOI: 10.1080/2162402X.2020.1847846.
- Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen J, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 5808-5817. PMID: 31227504, DOI: 10.1158/1078-0432.CCR-19-1025.
- Shin MS, Yim K, Moon K, Park HJ, Mohanty S, Kim JW, Montgomery RR, Shaw AC, Krishnaswamy S, Kang I. Dissecting alterations in human CD8+ T cells with aging by high-dimensional single cell mass cytometry. Clinical Immunology (Orlando, Fla.) 2019, 200: 24-30. PMID: 30659916, PMCID: PMC6443094, DOI: 10.1016/j.clim.2019.01.005.
- Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marte JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 99-109. PMID: 30131389, PMCID: PMC6320276, DOI: 10.1158/1078-0432.CCR-18-1512.
- Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 2836-2844. PMID: 30110194, PMCID: PMC6161834, DOI: 10.1200/JCO.2017.76.6212.
- Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O'Hear C, Vogelzang NJ. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncology 2018, 4: 537-544. PMID: 29423515, PMCID: PMC5885219, DOI: 10.1001/jamaoncol.2017.5440.
- Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. Clinical Genitourinary Cancer 2018, 16: e469-e476. PMID: 29137877, PMCID: PMC5878980, DOI: 10.1016/j.clgc.2017.10.010.
- Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. Journal Of Translational Medicine 2017, 15: 205. PMID: 29020960, PMCID: PMC5637331, DOI: 10.1186/s12967-017-1309-2.
- Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet. Oncology 2016, 17: 1590-1598. PMID: 27733243, PMCID: PMC5648054, DOI: 10.1016/S1470-2045(16)30496-X.
- Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2016, 57: 886-92. PMID: 26795292, PMCID: PMC6599519, DOI: 10.2967/jnumed.115.166512.
- Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/CCO.0000000000000177.
- Kim JW, Bilusic M, Plimack ER. Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield. Oncology (Williston Park, N.Y.) 2014, 28: 986-90. PMID: 25403631.
- Kim JW, Eder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology (Williston Park, N.Y.) 2014, 28 Suppl 3: 15-28. PMID: 25387682.
- Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly WK, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urologic Oncology 2014, 32: 637-44. PMID: 24840869, PMCID: PMC6771274, DOI: 10.1016/j.urolonc.2013.12.012.
- Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. Cancers 2012, 4: 1229-46. PMID: 24213505, PMCID: PMC3712729, DOI: 10.3390/cancers4041229.
- Kim JW, Marshall JL. Improving harmonious precision. Oncology (Williston Park, N.Y.) 2012, 26: 949, 954. PMID: 23176007.
- Kim JW. ASCO beyond McCormick: perseverance, collaboration, mentorship. Community Oncology 2012, 9: 265. PMID: 23028260, PMCID: PMC3460519, DOI: 10.1016/j.cmonc.2012.07.004.
- Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opinion On Biological Therapy 2012, 12: 463-78. PMID: 22413824, PMCID: PMC3482162, DOI: 10.1517/14712598.2012.668516.
- Kim JW, Madan RA, Gulley JL. Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. Clinical Genitourinary Cancer 2012, 10: 43-6. PMID: 22019260, PMCID: PMC3279569, DOI: 10.1016/j.clgc.2011.09.003.
- Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prevention Research (Philadelphia, Pa.) 2010, 3: 900-9. PMID: 20663981, PMCID: PMC2917478, DOI: 10.1158/1940-6207.CAPR-09-0131.
- Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJ, Old LJ, Cui Z. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7753-8. PMID: 16682640, PMCID: PMC1458507, DOI: 10.1073/pnas.0602382103.
- Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. Journal Of Neuro-oncology 2005, 72: 241-4. PMID: 15937647, DOI: 10.1007/s11060-004-2339-1.
Locations
Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511
Titles
- Associate Professor of Internal Medicine (Medical Oncology)
- Director, Prostate Cancer Research
Education & Training
- FellowNational Institutes of Health (2013)
- ResidentEmory University School of Medicine (2010)
- MDWake Forest University School of Medicine (2007)
Languages Spoken
- English
- 한국어 (Korean)
Additional Information
Honors & Recognitions
- Cancer Clinical Investigator Team Leadership Award (CCITLA): NCI (2021)
- Young Investigator Award: Conquer Cancer Foundation, American Society of Clinical Oncology (2013)
- Merit Award: Conqer Cancer Foundation, American Society of Clinical Oncology (2013)
Professional Service
- ASCO-SEP (2021 - Present): Editor
- Frontiers Oncology (2019 - Present): Reviewer
- Current Oncology Reports (2015 - Present): Editor
- American Association for Cancer Research (2014 - Present): Member
- Society of Immunotherapy of Cancer (2013 - Present): Member
- American Society of Clinical Oncology (2010 - Present): Member
Publications
- Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022 PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.
- Kim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.
- Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord JP, Gordon M, Kim JW, Sarkar I, Yuen K, Kadel EE, Mariathasan S, O'Hear C, Narayanan S, Fassò M, Carroll S, Powles T. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2021, 27: 3360-3369. PMID: 33568344, DOI: 10.1158/1078-0432.CCR-20-1981.
- Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU International 2021, 127: 435-444. PMID: 32969563, PMCID: PMC8265825, DOI: 10.1111/bju.15227.
- Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology 2020, 9: 1847846. PMID: 33312760, PMCID: PMC7714520, DOI: 10.1080/2162402X.2020.1847846.
- Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen J, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM. First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 5808-5817. PMID: 31227504, DOI: 10.1158/1078-0432.CCR-19-1025.
- Shin MS, Yim K, Moon K, Park HJ, Mohanty S, Kim JW, Montgomery RR, Shaw AC, Krishnaswamy S, Kang I. Dissecting alterations in human CD8+ T cells with aging by high-dimensional single cell mass cytometry. Clinical Immunology (Orlando, Fla.) 2019, 200: 24-30. PMID: 30659916, PMCID: PMC6443094, DOI: 10.1016/j.clim.2019.01.005.
- Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marte JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2019, 25: 99-109. PMID: 30131389, PMCID: PMC6320276, DOI: 10.1158/1078-0432.CCR-18-1512.
- Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 2836-2844. PMID: 30110194, PMCID: PMC6161834, DOI: 10.1200/JCO.2017.76.6212.
- Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O'Hear C, Vogelzang NJ. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncology 2018, 4: 537-544. PMID: 29423515, PMCID: PMC5885219, DOI: 10.1001/jamaoncol.2017.5440.
- Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. Clinical Genitourinary Cancer 2018, 16: e469-e476. PMID: 29137877, PMCID: PMC5878980, DOI: 10.1016/j.clgc.2017.10.010.
- Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. Journal Of Translational Medicine 2017, 15: 205. PMID: 29020960, PMCID: PMC5637331, DOI: 10.1186/s12967-017-1309-2.
- Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet. Oncology 2016, 17: 1590-1598. PMID: 27733243, PMCID: PMC5648054, DOI: 10.1016/S1470-2045(16)30496-X.
- Apolo AB, Lindenberg L, Shih JH, Mena E, Kim JW, Park JC, Alikhani A, McKinney YY, Weaver J, Turkbey B, Parnes HL, Wood LV, Madan RA, Gulley JL, Dahut WL, Kurdziel KA, Choyke PL. Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2016, 57: 886-92. PMID: 26795292, PMCID: PMC6599519, DOI: 10.2967/jnumed.115.166512.
- Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/CCO.0000000000000177.
- Kim JW, Bilusic M, Plimack ER. Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield. Oncology (Williston Park, N.Y.) 2014, 28: 986-90. PMID: 25403631.
- Kim JW, Eder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology (Williston Park, N.Y.) 2014, 28 Suppl 3: 15-28. PMID: 25387682.
- Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly WK, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urologic Oncology 2014, 32: 637-44. PMID: 24840869, PMCID: PMC6771274, DOI: 10.1016/j.urolonc.2013.12.012.
- Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. Cancers 2012, 4: 1229-46. PMID: 24213505, PMCID: PMC3712729, DOI: 10.3390/cancers4041229.
- Kim JW, Marshall JL. Improving harmonious precision. Oncology (Williston Park, N.Y.) 2012, 26: 949, 954. PMID: 23176007.
- Kim JW. ASCO beyond McCormick: perseverance, collaboration, mentorship. Community Oncology 2012, 9: 265. PMID: 23028260, PMCID: PMC3460519, DOI: 10.1016/j.cmonc.2012.07.004.
- Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opinion On Biological Therapy 2012, 12: 463-78. PMID: 22413824, PMCID: PMC3482162, DOI: 10.1517/14712598.2012.668516.
- Kim JW, Madan RA, Gulley JL. Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. Clinical Genitourinary Cancer 2012, 10: 43-6. PMID: 22019260, PMCID: PMC3279569, DOI: 10.1016/j.clgc.2011.09.003.
- Kim JW, Amin AR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prevention Research (Philadelphia, Pa.) 2010, 3: 900-9. PMID: 20663981, PMCID: PMC2917478, DOI: 10.1158/1940-6207.CAPR-09-0131.
- Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJ, Old LJ, Cui Z. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103: 7753-8. PMID: 16682640, PMCID: PMC1458507, DOI: 10.1073/pnas.0602382103.
- Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. Journal Of Neuro-oncology 2005, 72: 241-4. PMID: 15937647, DOI: 10.1007/s11060-004-2339-1.
Locations
Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511
Yale Cancer Center - Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Ste North Pavilion 8
New Haven, CT 06511
- Yale Cancer Center - Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste North Pavilion 8New Haven, CT 06511